Your browser doesn't support javascript.
LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis
Annals of Oncology ; 31:S1201-S1202, 2020.
Article in English | PMC | ID: covidwho-1384954
ABSTRACT

Background:

SARS-CoV-2 is associated with diverse clinical presentations ranging from asymptomatic infection to lethal complications. Small studies have suggested inferior outcomes in patients (pts) on active cancer treatment. This finding was not independently validated in our prior report on 928 pts, which included treatments administered within 4 weeks of COVID-19 diagnosis. Here, we examine outcomes related to systemic cancer treatment within one year of lab-confirmed SARS-CoV-2 infection in an expanded cohort. Method(s) The COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) was queried for pts ever receiving systemic treatment. Treatment type, cancer type, stage, and COVID-19 outcomes were examined. Pts were stratified by time from last treatment administration <2 wk, 2-4 wk, 1-3 mo, or 3-12 mo. Standardized incidence ratios (SIR) of mortality by treatment type and timing were calculated. Result(s) As of 31 July 2020, we analyzed 3920 pts;42% received systemic anti-cancer treatment within 12 mo (Table). 159 distinct medications were administered. The highest rate of COVID-19-associated complications were observed in pts treated within 1-3 months prior to COVID-19;all-cause mortality in this group was 26%. 30-day mortality by most recent treatment type was 20% for chemotherapy, 18% for immunotherapy, 17% for chemoradiotherapy, 29% for chemoimmunotherapy, 20% for targeted therapy, and 11% for endocrine therapy. SIR of mortality was highest for chemoimmunotherapy or chemotherapy <2 wks, and lowest for endocrine treatments. A high SIR was also found for targeted agents within 3-12 mo. Pts untreated in the year prior to COVID-19 diagnosis had a mortality of 14%. [Formula presented] Conclusion(s) 30-day mortality was highest amongst cancer pts treated 1-3 months prior to COVID-19 diagnosis and those treated with chemoimmunotherapy. Except for endocrine therapy, mortality for subgroups was numerically higher than in pts untreated within a year prior to COVID-19 diagnosis. Clinical trial identification NCT04354701. Legal entity responsible for the study The COVID-19 and Cancer Consortium (CCC19). Funding(s) National Cancer Institute (P30 CA068485). Disclosure T.M. Wise-Draper Research grant/Funding (self), Travel/Accommodation/Expenses AstraZeneca;Research grant/Funding (self) BMS;Research grant/Funding (self) Tesaro/GSK;Advisory/Consultancy Shattuck Labs;Leadership role, Travel/Accommodation/Expenses, HNC POA Lead Caris Life Sciences;Research grant/Funding (self), Travel/Accommodation/Expenses Merck;Travel/Accommodation/Expenses Eli Lilly;Travel/Accommodation/Expenses Bexion. A. Elkrief Research grant/Funding (self) AstraZeneca. B.I. Rini Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses Merck;Advisory/Consultancy, Research grant/Funding (self) Roche;Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses Pfizer;Advisory/Consultancy, Research grant/Funding (self) AVEO;Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses BMS;Advisory/Consultancy arravive;Advisory/Consultancy 3D medicines;Advisory/Consultancy Synthorx;Advisory/Consultancy Surface Oncology;Shareholder/Stockholder/Stock options PTC Therapeutics;Research grant/Funding (self) AstraZeneca. D.B. Johnson Advisory/Consultancy Array Biopharma;Advisory/Consultancy, Research grant/Funding (self) BMS;Advisory/Consultancy Janssen;Advisory/Consultancy Merck;Advisory/Consultancy Novartis;Research grant/Funding (self) Incyte;Leadership role ASCO melanoma scientific committee chair;Leadership role NCCN Melanoma committee. G. Lopes Honoraria (self), Travel/Accommodation/Expenses Boehringer Ingelheim;Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses Pfizer;Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution) AstraZeneca;Research grant/Funding (institution) Merck;Research grant/Funding (institution) EMD Serono;Research gr

Full text: Available Collection: Databases of international organizations Database: PMC Language: English Journal: Annals of Oncology Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: PMC Language: English Journal: Annals of Oncology Year: 2020 Document Type: Article